Sentinel Lymph Node Mapping in the Management of Cervical Cancer
Fig. 34.1 A External iliac artery region: lymph nodes that are attached to the external iliac artery and vein from the bifurcation till groin; B Obturator region: lymph nodes around…
Fig. 34.1 A External iliac artery region: lymph nodes that are attached to the external iliac artery and vein from the bifurcation till groin; B Obturator region: lymph nodes around…
Fig. 43.1 The learning curve for self-taught laparoscopic colorectal surgery is up to 150 procedures (Adapted from Miskovic et al. [1]) 43.2 Educational Challenges in Rectal Cancer Surgery Rectal cancer…
#RC Period Neo-bladder Cont. cut Conduit UC TUUC Anal Unknown no diversion Others Ann Arbor 643 95–04 45.1 1.4 53.5 – – – – 962 00–09 40.0 2.0 58.0…
Fig. 15.1 (a) Bladder lesion. (b) Bipolar resectoscope. (c) Post transurethral resection image 15.5 Partial Cystectomy Partial cystectomy provides a feasible approach in a select group of bladder cancer patients…
Description Treatment Special considerations Anal Intraepithelial Neoplasia (AIN) Dysplasia of squamous cells of the anal margin/canal; precursor lesion of SCC Surveillance for low-grade lesions Common in HIV + HIV…
Fig. 30.1 Overall survival rates for patients treated with or without adjuvant pelvic radiation therapy for low-intermediate-risk or high-intermediate-risk endometrial cancer on Gynecologic Oncology Group trial GOG-99 (Reprinted from Keys…
Fig. 55.1 Treatment algorithm As is evidenced by the NCCN guidelines for the treatment of rectal cancer with resectable liver metastasis, there is no defined algorithm for the initial treatment…
Fig 47.1 TEMS rectoscope with the binocular eye-piece and the instruments in the appropriate ports Procedure The procedure is performed under general anesthetic with full muscle relaxation, as for abdominal…
Fig. 35.1 Overall survival comparison for NACT in surgical setting from NACCMA Collaboration meta-analysis (From Tierney et al. [13]; used with permission from Elsevier) In 2007 the Gynecologic Oncology Group…
Molecular lesion Type I (%) Type II (%) References PIK3CA Mutation 30 20 [20, 81–83, 122] Amplification 2–14 46 [42, 122] KRAS mutation 11–26 2 [119, 123, 124] AKT mutation…